These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy? van Koningsbruggen-Rietschel S; Naehrlich L Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480 [No Abstract] [Full Text] [Related]
3. Homozygosity for L997F in a child with normal clinical and chloride secretory phenotype provides evidence that this cystic fibrosis transmembrane conductance regulator mutation does not cause cystic fibrosis. Derichs N; Schuster A; Grund I; Ernsting A; Stolpe C; Körtge-Jung S; Gallati S; Stuhrmann M; Kozlowski P; Ballmann M Clin Genet; 2005 Jun; 67(6):529-31. PubMed ID: 15857421 [No Abstract] [Full Text] [Related]
4. R248G cystic fibrosis transmembrane conductance regulator mutation in three siblings presenting with recurrent acute pancreatitis and reproductive issues: a case series. Villalona S; Glover-López G; Ortega-García JA; Moya-Quiles R; Mondejar-López P; Martínez-Romero MC; Rigabert-Montiel M; Pastor-Vivero MD; Sánchez-Solís M J Med Case Rep; 2017 Feb; 11(1):42. PubMed ID: 28196530 [TBL] [Abstract][Full Text] [Related]
5. CFTR modulation for young children with cystic fibrosis. Yammine S; Singer F; Latzin P Lancet Respir Med; 2016 Feb; 4(2):84-5. PubMed ID: 26803278 [No Abstract] [Full Text] [Related]
6. A novel nonsense mutation, S466Xa in exon 10 of the cystic fibrosis transmembrane conductance regulator gene. Mittre H; Barre M; Leymarie P Hum Mutat; 1996; 8(4):392-3. PubMed ID: 8956053 [No Abstract] [Full Text] [Related]
7. Cystic fibrosis and bone disease: defective osteoblast maturation with the F508del mutation in cystic fibrosis transmembrane conductance regulator. Velard F; Delion M; Le Henaff C; Guillaume C; Gangloff S; Jacquot J; Tabary O; Touqui L; Barthes F; Sermet-Gaudelus I Am J Respir Crit Care Med; 2014 Mar; 189(6):746-8. PubMed ID: 24628315 [No Abstract] [Full Text] [Related]
8. Combating cystic fibrosis: in search for CF transmembrane conductance regulator (CFTR) modulators. Noy E; Senderowitz H ChemMedChem; 2011 Feb; 6(2):243-51. PubMed ID: 21275046 [No Abstract] [Full Text] [Related]
9. Sweat chloride concentration in cystic fibrosis patients with cystic fibrosis trans-membrane conductance regulator I1234V mutation. Abdul-Wahab A; Janahi IA; Abdel-Rahman MO Saudi Med J; 2009 Aug; 30(8):1101-2. PubMed ID: 19668897 [No Abstract] [Full Text] [Related]
10. Novel de novo large deletion in cystic fibrosis transmembrane conductance regulator gene results in a severe cystic fibrosis phenotype. Norek A; Stremska M; Sobczyńska-Tomaszewska A; Wertheim-Tysarowska K; Dmeńska H; Jurek M J Pediatr; 2011 Aug; 159(2):343-6.e1. PubMed ID: 21663921 [TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis transmembrane conductance regulator mutation spectrum in patients with cystic fibrosis in Tunisia. Fredj SH; Messaoud T; Templin C; des Georges M; Fattoum S; Claustres M Genet Test Mol Biomarkers; 2009 Oct; 13(5):577-81. PubMed ID: 19715466 [TBL] [Abstract][Full Text] [Related]
12. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review. Yang H; Ma T Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311 [TBL] [Abstract][Full Text] [Related]
13. Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients. Asmus E; Karle W; Brack MC; Wittig C; Behrens F; Reinshagen L; Pfeiffer M; Schulz S; Mandzimba-Maloko B; Erfinanda L; Perret PL; Michalick L; Smeele PJ; Lim EHT; van den Brom CE; Vonk ABA; Kaiser T; Suttorp N; Hippenstiel S; Sander LE; Kurth F; Rauch U; Landmesser U; Haghikia A; Preissner R; Bogaard HJ; Witzenrath M; Kuebler WM; Szulcek R; Simmons S Eur Respir J; 2023 Mar; 61(3):. PubMed ID: 36958745 [TBL] [Abstract][Full Text] [Related]
16. A splicing mutation in intron 16 of the cystic fibrosis transmembrane conductance regulator gene, associated with severe disease, is common on Reunion Island. Bienvenu T; Cartault F; Lesure F; Renouil M; Beldjord C; Kaplan JC Hum Hered; 1996; 46(3):168-71. PubMed ID: 8860012 [TBL] [Abstract][Full Text] [Related]
17. Sweat chloride concentration in cystic fibrosis patients with cystic fibrosis trans-membrane conductance regulator 11234V mutation. Al-Mendalawi MD; Abdul-Wahab A; Janahi IA; Abdel-Rahman MO Saudi Med J; 2010 Mar; 31(3):339-40; author reply 340. PubMed ID: 20231949 [No Abstract] [Full Text] [Related]
18. Pharmacogenetics of cystic fibrosis treatment. Carter SC; McKone EF Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265 [TBL] [Abstract][Full Text] [Related]
19. Identification of four novel mutations in the cystic fibrosis transmembrane conductance regulator gene: E664X, 2113delA, 306delTAGA, and delta M1140. Clavel C; Pennaforte F; Pigeon F; Verlingue C; Birembaut P; Férec C Hum Mutat; 1997; 9(4):368-9. PubMed ID: 9101301 [No Abstract] [Full Text] [Related]